Lead Product(s) : OTL-103
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Orchard Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Orchard Licenses Gene Therapy Technology from GSK
Details : Orchard has entered into this license agreements with GSK for use of their lentiviral stable cell line technology for Orchard’s investigational hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassem...
Product Name : OTL-103
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : OTL-103
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Orchard Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
